Loughborough, England, July 21, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. ( NMRD) (“Nemaura” or the “Firm”), a medical expertise firm targeted on creating and commercializing a every day disposable, wearable glucose sensor and supporting personalised life-style teaching packages, right this moment introduced that it has been granted a UK trademark for “Meta Rating,” a time period the Firm plans to make use of as a digital biomarker for its client metabolic well being program. Trademark functions at the moment are pending in a number of different main international territories.
Meta Rating would be the metric and digital biomarker the Firm will use as a part of its client packages. This digital biomarker will derive output from Nemaura’s glucose sensor together with quite a lot of behavioral inputs of customers. These client packages goal the pre-diabetes and weight problems markets, with over 87 million folks within the U.S. alone with pre-diabetes.
“We imagine that proudly owning the outline of measurement for the biomarker utilized within the Miboko program is a crucial differentiation amongst the entire numerous metabolic well being packages presently out there,” commented Nemaura CEO Faz Chowdhury, Ph.D. “Whereas there are lots of medical measurements that docs depend on to know an individual’s metabolic well being, by creating and branding a simple-to-describe rating now we have created a way to simply observe metabolic well being and show progress whereas utilizing our sensor that’s simple to put on.”
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical expertise firm creating and commercializing non-invasive wearable diagnostic units. The corporate is presently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark accredited Class IIb medical gadget, is a non-invasive and versatile steady glucose monitor (CGM) offering actionable insights derived from actual time glucose measurements and every day glucose pattern information, which can assist folks with diabetes and pre-diabetes to raised handle, reverse, and stop the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Software) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose information processed utilizing synthetic intelligence and a digital healthcare subscription service within the U.S. as a normal wellness product as a part of its BEAT®diabetes program that’s presently present process pilot research.
Moreover, Nemaura has launched a beta trial of Miboko, a metabolic well being and well-being program utilizing a non-invasive glucose sensor together with an AI cellular utility that helps a person perceive how sure meals and life-style habits can affect one’s general metabolic well being and well-being. Nemaura believes that as much as half the inhabitants may gain advantage from a sensor and program that displays metabolic well being and well-being.
The Firm sits on the intersection of the worldwide Sort 2 diabetes market that’s anticipated to achieve almost $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight reduction and wellness functions that’s estimated to achieve $60 billion by 2023.
For extra data, please go to www.NemauraMedical.com.
Cautionary Assertion Relating to Ahead-Trying Statements:
The statements on this press launch that aren’t historic info might represent forward-looking statements which can be based mostly on present expectations and are topic to dangers and uncertainties that might trigger precise future outcomes to vary materially from these expressed or implied by such statements. These dangers and uncertainties embody, however aren’t restricted to, the launch of proBEAT™ within the U.S., dangers associated to regulatory standing and the failure of future improvement and preliminary advertising efforts, Nemaura Medical’s capacity to safe extra industrial partnering preparations, dangers and uncertainties regarding Nemaura Medical and its companions’ capacity to develop, market and promote proBEAT™, the supply of considerable extra fairness or debt capital to help its analysis, improvement and product commercialization actions, and the success of its analysis, improvement, regulatory approval, advertising and distribution plans and methods, together with these plans and methods associated to each proBEAT™ digital well being, and sugarBEAT®. There will be no assurance that the corporate will be capable of attain part of or any of the worldwide marketplace for CGM with its merchandise/providers. The U.S. Meals and Drug Administration (the “FDA”) reserves the fitting to re-evaluate its choice that proBEAT™ qualifies as a normal wellness product ought to it turn out to be conscious of any points corresponding to pores and skin irritation or different hostile occasions from the gadget, in addition to any misuse impacting affected person security, and some other cause because the FDA might even see match at its discretion to find out the product doesn’t match the definition of a normal wellness product. These and different dangers and uncertainties are recognized and described in additional element in Nemaura Medical’s filings with the USA Securities and Change Fee, together with, with out limitation, its Annual Report on Kind 10-Okay for probably the most just lately accomplished fiscal 12 months, its Quarterly Stories on Kind 10-Q, and its Present Stories on Kind 8-Okay. Nemaura Medical undertakes no obligation to publicly replace or revise any forward-looking statements.